"Niacin adverse events disputed in AIM-HIGH and HPS2-THRIVE"
Heart Mar 26
http://www.theheart.org/article/1522371.do 
"Boden is referring to the adverse events in the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE). Right now both camps appear to have taken different sides in interpreting the adverse events in the AIM-HIGH study. Whereas Boden is cautious in making too much of the small number of adverse events in AIM-HIGH, the HPS2-THRIVE investigators, including principal investigator Dr Jane Armitage (Oxford University, UK) and co-director Dr Rory Collins (Oxford University), believe the findings from AIM-HIGH support their study results. They issued a press release stating that the AIM-HIGH results are consistent with what they observed in HPS2-THRIVE and that in light of these findings, "the use of all niacin products used to treat lipids should now be reconsidered." . . . "